ISTH 2023 | Emicizumab for hemophilia A: interim analysis of the real-world EMIIL study
Johannes Oldenburg, MD, University Clinic Bonn, Bonn, Germany, shares the results of an interim analysis of the EMIIL study (ISRCTN58752772), a multicenter non-interventional real-world study of emicizumab for patients of all ages with severe hemophilia A with and without FVIII inhibitors. The primary outcome of this study was the annualized bleeding rate (ABR), which was reduced from baseline at the time of analysis and was lower for patients under 12 years old. Prof. Oldenburg also shares the promising safety data from the study so far. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
JO: reimbursed for attending symposia/congresses and/or received honoraria and/or funds for research from Bayer, Biogen Idec, Biomarin, Biotest, Chugai, CSL Behring, Freeline, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Spark Therapeutics, Swedish Orphan Biovitrum and Takeda.
